PriceTargets.com logo

NASDAQ:RPTX - Repare Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $39.40
  • Forecasted Upside: 44.59 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$27.25 As of 03/5/2021 01:00 AM ET
▼ -0.17 (-0.62%)
1 month | 3 months | 12 months
Get New Repare Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RPTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RPTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$39.40
▲ +44.59% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Repare Therapeutics in the last 3 months. The average price target is $39.40, with a high forecast of $51.00 and a low forecast of $27.00. The average price target represents a 44.59% upside from the last price of $27.25.
Buy
The current consensus among 7 contributing investment analysts is to buy stock in Repare Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/12/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/11/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2020
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2020
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2021
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/5/2021

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2021Berenberg BankInitiated CoverageBuy$51.00Low
i
12/29/2020Northland SecuritiesReiterated RatingTop PickN/A
i
12/16/2020Morgan StanleyBoost Price TargetOverweight$37.00 ➝ $41.00High
i
Rating by Jeffrey Hung at Morgan Stanley
10/28/2020Northland SecuritiesInitiated CoverageOutperform$38.00Medium
i
9/17/2020Bloom BurtonReiterated RatingBuyHigh
i
Rating by D. Martin at Bloom Burton
7/14/2020Morgan StanleyInitiated CoverageOverweight$37.00High
i
7/14/2020CowenInitiated CoverageOutperformHigh
i
7/14/2020The Goldman Sachs GroupInitiated CoverageNeutral$27.00High
i
7/14/2020Piper SandlerInitiated CoverageOverweight$40.00High
i
(Data available from 3/6/2016 forward)
Repare Therapeutics logo
Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada. The company use its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing CCNE1-SL inhibitor, a proprietary drug discovery program for tumors with amplification of CCNE1; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was founded in 2016 and is headquartered in Montréal, Canada.
Read More

Today's Range

Now: $27.25
$24.25
$29.43

50 Day Range

MA: $35.81
$27.42
$44.04

52 Week Range

Now: $27.25
$21.45
$46.44

Volume

251,260 shs

Average Volume

138,066 shs

Market Capitalization

$1.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Repare Therapeutics?

The following equities research analysts have issued stock ratings on Repare Therapeutics in the last year: Berenberg Bank, Bloom Burton, Cowen Inc, Morgan Stanley, Northland Securities, Piper Sandler, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for RPTX.

What is the current price target for Repare Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Repare Therapeutics in the last year. Their average twelve-month price target is $39.40, suggesting a possible upside of 43.7%. Berenberg Bank has the highest price target set, predicting RPTX will reach $51.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $27.00 for Repare Therapeutics in the next year.
View the latest price targets for RPTX.

What is the current consensus analyst rating for Repare Therapeutics?

Repare Therapeutics currently has 1 hold rating, 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RPTX will outperform the market and that investors should add to their positions of Repare Therapeutics.
View the latest ratings for RPTX.

What other companies compete with Repare Therapeutics?

Other companies that are similar to Repare Therapeutics include I-Mab, ChemoCentryx, Insmed, Apellis Pharmaceuticals, Hypera, Arvinas, Agios Pharmaceuticals, Karuna Therapeutics, MorphoSys, Legend Biotech, FibroGen, ALX Oncology, Pacira BioSciences, Viela Bio and Alkermes.

How do I contact Repare Therapeutics' investor relations team?

Repare Therapeutics' physical mailing address is 7210 Frederick-Banting Suite 100, St-Laurent A8, H4S 2A1. The company's listed phone number is 857-412-7018 and its investor relations email address is [email protected] The official website for Repare Therapeutics is www.reparerx.com.